# Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases

> **NCT06685042** · PHASE1,PHASE2 · RECRUITING · sponsor: **Fondazione Policlinico Universitario Agostino Gemelli IRCCS** · enrollment: 8 (estimated)

## Conditions studied

- Lupus Erythematosus, Systemic
- System; Sclerosis
- ANCA Associated Vasculitis
- Dermatomyositis
- Polymyositis

## Interventions

- **BIOLOGICAL:** CAR T cell

## Key facts

- **NCT ID:** NCT06685042
- **Lead sponsor:** Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-29
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2025-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06685042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06685042, "Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT06685042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*